⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22233087 | 1.00 | — | — | |
| SCHEMBL22256503 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL30339018 | 0.98 | — | — | |
| SCHEMBL25819471 | 0.89 | — | — | |
| SCHEMBL25189077 | 0.88 | TRPM5 (0.35) | — | |
| SCHEMBL31087334 | 0.88 | TRPM5 (0.35) | — | |
| SCHEMBL27054181 | 0.88 | EPAS1 (0.36) | — | |
| SCHEMBL22444805 | 0.88 | TRPM5 (0.35) | — | |
| SCHEMBL22444804 | 0.88 | TRPM5 (0.35) | — | |
| Hydrochloric Acid SCHEMBL30020455 | 0.86 | EPAS1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709722-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709716-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4430037-B1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-04-17 | — | — | US | disclosed |
| CN-119731170-A | Isoxazolidines as RIPK1 inhibitors and their use | 建新公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | VORONOI INC. (KR) | 2025-01-16 | — | — | US | disclosed |
| WO-2024233547-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024233554-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4430037-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4421077-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | Voronoi Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023083847-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-05-19 | — | — | WO | disclosed |
| US-20220242870-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | VORONOIBIO INC. (KR) | 2022-08-04 | — | — | US | disclosed |
| WO-2022131741-A1 | ISOXAZOLIDINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2022-06-23 | — | — | WO | disclosed |
| EP-3971190-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020235902-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | 주식회사 보로노이 (KR) | 2020-11-26 | — | — | WO | disclosed |
| EP-3732176-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-11-04 | — | — | EP | disclosed |
| CN-111741957-A | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-10-02 | — | — | CN | disclosed |
| WO-2020149553-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR TREATMENT OF KINASE-RELATED DISEASE | 주식회사 보로노이 | 2020-07-23 | — | — | WO | disclosed |
| WO-2020149553-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR TREATMENT OF KINASE-RELATED DISEASE | 주식회사 보로노이 | 2020-07-23 | — | — | WO | disclosed |
| WO-2020043173-A1 | HETEROCYCLIC COMPOUND AS RECEPTOR INTERACTING PROTEIN 1(RIP1) KINASE INHIBITOR | 宁波文达医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |